Mary Caffrey

Coverage of clinical trial results presented across a range of solid tumor cancers, including breast, ovarian, colorectal, and non-small cell lung cancer, among other types; as well as important findings in genomic testing.

An overview of the 2023 recommendations on myelodysplastic syndromes by Guillermo Garcia-Mareno, MD, of MD Anderson Cancer Center, appears in the August issue of the American Journal of Hematology.

Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, expands on the patient characteristics and potential impacts of COVID-19 on SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide.

With a broad research focus on heart disease risk reduction through the development of novel treatment strategies, Stephen Nicholls, MBBS, PhD, Monash University and Victorian Heart Hospital, Melbourne, Australia. discusses contributions in the space from therapies with systemwide effects.

The Enhancing Oncology Model (EOM) attracted more than 2800 practitioners across 561 sites of care; a group of practices in the American Oncology Network enrolled under a single tax ID number.

A well-regarded tool for predicting prognosis in myelodysplastic syndromes is updated to incorporate mutations and tested with real-world data.

While the final number of EOM practices will be fewer than the numbers in the OCM, the presence of Tennessee Oncology, Texas Oncology, and Northwest Medical Specialties will ensure participation of key leaders who succeeded in the OCM and have weighed in on what's needed in its replacement.

Speakers elaborated on health care delivery and regulatory policy posters presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. This article will appear in the ASCO recap edition of Evidence-Based Oncology.

The study's lead author said patients would experience improved quality of life due to fewer transfusions and fewer trips to the clinic to receive treatment.

Ahead of tonight's deadline for practices to decide whether to join the Enhancing Oncology Model, CMS published a list of participants that is already outdated. A possible flaw in the model's breast cancer methodology has some practices weighing their options.

Approximately 2500 individuals in the United States could be eligible to receive valoctocogene roxaparvovec.

Presentations on the first day of the 2023 American Society of Clinical Oncology Annual Meeting covered data on a split dose CAR T-cell therapy and a CAR T therapy manufactured with TKI.

The bispecific antibody received an accelerated approval in May to treat patients with R/R diffuse large B-cell lymphoma.

Abstracts were presented in a session on metastatic lung cancer on the final day of the 2023 American Society of Clinical Oncology Annual Meeting.

The therapy, to be marketed as Elevidys, is approved for the treatment of ambulatory pediatric patients aged 4 through 5 years with DMD who have a confirmed mutation in the DMD gene.

The therapy is designed to target multiple receptors and could address an unmet need in metastatic colorectal cancer.

Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, California, discusses the need for novel treatments for patients with diffuse large B-cell lymphoma (DLBCL).

The health plans, which have announced their intent to join forces, retired $345,000 in debt in the areas they serve.

Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, CA, discussed the utility of epcoritamab in diffuse large B-cell lymphoma (DLBCL) and the potential impacts the bispecific antibody's recent approval will have in the community oncology setting.

The session, “Payment Reform: Lessons Learned from the Oncology Care Model (OCM) and Implications for the Enhancing Oncology Model (EOM)," comes less than a month before the EOM is set to begin.

Judy Wang, MD, medical oncologist and clinical trials investigator at Sarah Cannon Research Institute at Florida Cancer Specialists & Research Institute, discussed the mechanism of action and rationale for studying CLN-619, an anti-MICA/B antibody, with and without pembrolizumab in patients with solid tumors.

In early findings, the antibody drug conjugate created strong responses in multiple tumor types where patients have unmet need.

Bhagirathbhai R. Dholaria, MD, assistant professor of medicine in the Department of Hematology-Oncology at Vanderbilt University Medical Center, discussed findings from the phase 2 TRiMM-2 trial of talquetamab plus daratumumab in multiple myeloma.

The confirmatory trial showed limited side effects relative to physician's choice of chemotherapy.